AR082446A1 - N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas - Google Patents
N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidasInfo
- Publication number
- AR082446A1 AR082446A1 ARP110102785A ARP110102785A AR082446A1 AR 082446 A1 AR082446 A1 AR 082446A1 AR P110102785 A ARP110102785 A AR P110102785A AR P110102785 A ARP110102785 A AR P110102785A AR 082446 A1 AR082446 A1 AR 082446A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- amino
- oxygen
- halo
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 28
- 125000000217 alkyl group Chemical group 0.000 abstract 20
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 17
- 229910052736 halogen Inorganic materials 0.000 abstract 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 16
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 14
- 229910052760 oxygen Inorganic materials 0.000 abstract 14
- 239000001301 oxygen Substances 0.000 abstract 14
- 229910052757 nitrogen Inorganic materials 0.000 abstract 13
- 150000002367 halogens Chemical group 0.000 abstract 12
- 125000004122 cyclic group Chemical group 0.000 abstract 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 10
- 229910052717 sulfur Inorganic materials 0.000 abstract 10
- 239000011593 sulfur Substances 0.000 abstract 10
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 9
- 229910052799 carbon Inorganic materials 0.000 abstract 8
- 125000004432 carbon atom Chemical group C* 0.000 abstract 8
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 125000005842 heteroatom Chemical group 0.000 abstract 7
- 125000006413 ring segment Chemical group 0.000 abstract 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 6
- 125000002947 alkylene group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000000262 haloalkenyl group Chemical group 0.000 abstract 6
- 125000000232 haloalkynyl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 5
- 125000004434 sulfur atom Chemical group 0.000 abstract 5
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- -1 halo C1-4 alkyl Chemical group 0.000 abstract 2
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000011737 fluorine Chemical group 0.000 abstract 1
- 229910052731 fluorine Chemical group 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37061210P | 2010-08-04 | 2010-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082446A1 true AR082446A1 (es) | 2012-12-05 |
Family
ID=44503821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102785A AR082446A1 (es) | 2010-08-04 | 2011-08-02 | N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9290485B2 (enExample) |
| EP (1) | EP2601189B1 (enExample) |
| JP (1) | JP5809267B2 (enExample) |
| KR (1) | KR20130096253A (enExample) |
| CN (1) | CN103080104B (enExample) |
| AR (1) | AR082446A1 (enExample) |
| AU (1) | AU2011287574B2 (enExample) |
| CA (1) | CA2806015A1 (enExample) |
| EA (1) | EA021359B1 (enExample) |
| ES (1) | ES2542764T3 (enExample) |
| MX (1) | MX2013001363A (enExample) |
| TW (1) | TW201206900A (enExample) |
| UY (1) | UY33541A (enExample) |
| WO (1) | WO2012017020A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| WO2013025858A1 (en) * | 2011-08-16 | 2013-02-21 | Glaxosmithkline Llc | 5-benzyl-n-phenyethyl-1,3,4-oxadiazole-2-carboxamide derivatives |
| TWI596089B (zh) * | 2012-04-17 | 2017-08-21 | 富士軟片股份有限公司 | 含氮雜環化合物或其鹽 |
| GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| PH12015501492B1 (en) | 2013-01-08 | 2015-09-28 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| GB201300304D0 (en) * | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
| RU2712621C2 (ru) * | 2013-05-23 | 2020-01-30 | Калвиста Фармасьютикалз Лимитед | Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| MX366498B (es) * | 2013-08-14 | 2019-07-11 | Kalvista Pharmaceuticals Ltd | Inhibidores de calicreina plasmatica. |
| GB2517908A (en) * | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
| CN105683167B (zh) | 2013-10-16 | 2018-10-23 | 富士胶片株式会社 | 含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂 |
| KR20160106627A (ko) * | 2013-12-30 | 2016-09-12 | 라이프에스씨아이 파마슈티컬스, 인크. | 치료적 억제 화합물 |
| US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| EP3169325B1 (en) * | 2014-07-16 | 2021-04-28 | Attune Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| EP3195866B1 (en) | 2014-08-22 | 2020-11-18 | FUJIFILM Corporation | Pharmaceutical composition for treating flt3 mutation-positive cancer, mutant flt3 inhibitor and uses thereof |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| JP6412471B2 (ja) | 2015-07-15 | 2018-10-24 | 富士フイルム株式会社 | 含窒素複素環化合物の製造方法およびその中間体 |
| JP6917988B2 (ja) * | 2015-10-27 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
| US10640486B2 (en) * | 2015-10-27 | 2020-05-05 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物 |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| JP6896701B2 (ja) * | 2016-02-26 | 2021-06-30 | 大日本住友製薬株式会社 | イミダゾリルアミド誘導体 |
| RU2739447C2 (ru) * | 2016-05-31 | 2020-12-24 | Калвиста Фармасьютикалз Лимитед | Производные пиразола в качестве ингибиторов калликреина |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| CN106214681B (zh) * | 2016-07-28 | 2018-05-08 | 三峡大学 | 化合物在制备抑制激肽释放酶klk7的药物上的应用及其合成方法 |
| CN106333949B (zh) * | 2016-07-28 | 2018-05-29 | 三峡大学 | 化合物在制备抑制激肽释放酶klk7的药物上的应用及其合成方法 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| JP7123809B2 (ja) * | 2016-12-20 | 2022-08-23 | 住友ファーマ株式会社 | 未分化ｉＰＳ細胞の除去剤 |
| JP6775483B2 (ja) * | 2016-12-20 | 2020-10-28 | 大日本住友製薬株式会社 | １，４−ジ置換イミダゾール誘導体からなる医薬 |
| WO2018200674A1 (en) * | 2017-04-26 | 2018-11-01 | Mitobridge, Inc. | Dynamin-1-like protein inhibitors |
| GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| IL274557B2 (en) * | 2017-11-29 | 2024-09-01 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibitor |
| US11142536B2 (en) * | 2018-10-03 | 2021-10-12 | Massachusetts Institute Of Technology | Macromolecules comprising triazoles |
| US11155527B2 (en) | 2018-10-03 | 2021-10-26 | Massachusetts Institute Of Technology | Macromolecules comprising triazoles and related compounds |
| AR116898A1 (es) * | 2018-10-30 | 2021-06-23 | H Lundbeck As | DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3 |
| GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
| WO2021028645A1 (en) * | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021026672A1 (en) | 2019-08-09 | 2021-02-18 | Novartis Ag | Heterocyclic wdr5 inhibitors as anti-cancer compounds |
| EP4017850A1 (en) * | 2019-08-21 | 2022-06-29 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| UA130303C2 (uk) | 2019-12-06 | 2026-01-14 | Вертекс Фармасьютикалз Інкорпорейтед | Заміщені тетрагідрофурани як модулятори натрієвих каналів |
| GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
| GB2591730A (en) | 2019-12-09 | 2021-08-11 | Kalvista Pharmaceuticals Ltd | New polymorphs |
| CN115210230A (zh) * | 2020-03-04 | 2022-10-18 | 南京明德新药研发有限公司 | 杂环类化合物 |
| MX2023000507A (es) * | 2020-07-10 | 2023-02-09 | Merck Sharp & Dohme Llc | Inhibidores de la calicreina plasmatica. |
| WO2022056051A1 (en) * | 2020-09-10 | 2022-03-17 | Merck Sharp & Dohme Corp. | Plasma kallikrein inhibitors |
| TW202228686A (zh) | 2020-10-15 | 2022-08-01 | 英商卡爾維斯塔製藥有限公司 | 血管性水腫之治療 |
| WO2022084693A1 (en) | 2020-10-23 | 2022-04-28 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
| US20240122909A1 (en) | 2021-02-09 | 2024-04-18 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
| PE20241335A1 (es) | 2021-06-04 | 2024-07-03 | Vertex Pharma | N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio |
| WO2023002219A1 (en) | 2021-07-23 | 2023-01-26 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
| PL4288036T3 (pl) | 2022-04-27 | 2024-11-25 | Kalvista Pharmaceuticals Limited | Preparaty inhibitora kalikreiny osoczowej |
| WO2024180100A1 (en) | 2023-02-27 | 2024-09-06 | Kalvista Pharmaceuticals Limited | New solid form of a plasma kallikrein inhibitor |
| WO2025001956A1 (zh) * | 2023-06-30 | 2025-01-02 | 远森制药（杭州）有限公司 | 杂芳族甲酰胺类化合物及其在医药上的应用 |
| WO2025172692A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
| WO2025172693A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US6664255B1 (en) * | 1999-05-19 | 2003-12-16 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
| HUP0300029A2 (en) | 2000-02-25 | 2003-05-28 | Hoffmann La Roche | Adenosine receptor modulators, pharmaceutical compositions containing them and their use |
| WO2001079261A1 (en) | 2000-04-14 | 2001-10-25 | Corvas International, Inc. | Tetrahydro-azepinone derivatives as thrombin inhibitors |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| AUPR649001A0 (en) | 2001-07-20 | 2001-08-09 | Holly, John Anthony | A precision seed and chemical placement implement |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| FR2836143B1 (fr) * | 2002-02-21 | 2004-04-16 | Servier Lab | Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| WO2004071440A2 (en) | 2003-02-06 | 2004-08-26 | Bristol-Myers Squibb Company | Thiazolyl-based compounds useful as kinase inhibitors |
| CA2541989C (en) | 2003-10-24 | 2013-10-01 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2006008194A1 (en) | 2004-07-23 | 2006-01-26 | Bayer Cropscience Sa | 3-pyridinylethylcarboxamide derivatives as fungicides |
| JP4969451B2 (ja) | 2004-11-16 | 2012-07-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）として有用な新規な複素環誘導体 |
| FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
| US20090209522A1 (en) | 2005-06-28 | 2009-08-20 | Graham Andrew Showell | Heterocyclic Non-Peptide GNRH Antagonists |
| AU2006325746A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| CA2658523C (en) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| GB0807828D0 (en) | 2008-04-29 | 2008-06-04 | Vantia Ltd | Aminopyridine derivatives |
| US20120040951A1 (en) | 2008-12-30 | 2012-02-16 | Claudio Chuaqui | Heteroaryl compounds useful as raf kinase inhibitors |
| WO2010108187A2 (en) | 2009-03-20 | 2010-09-23 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| US8946231B2 (en) | 2009-03-23 | 2015-02-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| EP3632899A1 (en) | 2009-05-29 | 2020-04-08 | RaQualia Pharma Inc. | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
| ES2433230T3 (es) | 2009-08-06 | 2013-12-10 | Merck Patent Gmbh | Compuestos bicíclicos novedosos de urea |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| CA2783801A1 (en) | 2009-12-18 | 2011-06-23 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
-
2011
- 2011-07-29 US US13/194,009 patent/US9290485B2/en not_active Expired - Fee Related
- 2011-08-02 AR ARP110102785A patent/AR082446A1/es unknown
- 2011-08-02 UY UY0001033541A patent/UY33541A/es not_active Application Discontinuation
- 2011-08-03 CN CN201180041505.7A patent/CN103080104B/zh not_active Expired - Fee Related
- 2011-08-03 MX MX2013001363A patent/MX2013001363A/es not_active Application Discontinuation
- 2011-08-03 KR KR1020137005250A patent/KR20130096253A/ko not_active Withdrawn
- 2011-08-03 EP EP11745519.6A patent/EP2601189B1/en not_active Not-in-force
- 2011-08-03 ES ES11745519.6T patent/ES2542764T3/es active Active
- 2011-08-03 WO PCT/EP2011/063389 patent/WO2012017020A1/en not_active Ceased
- 2011-08-03 TW TW100127620A patent/TW201206900A/zh unknown
- 2011-08-03 EA EA201300200A patent/EA021359B1/ru not_active IP Right Cessation
- 2011-08-03 CA CA2806015A patent/CA2806015A1/en not_active Abandoned
- 2011-08-03 AU AU2011287574A patent/AU2011287574B2/en not_active Ceased
- 2011-08-03 JP JP2013522243A patent/JP5809267B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5809267B2 (ja) | 2015-11-10 |
| US9290485B2 (en) | 2016-03-22 |
| EA201300200A1 (ru) | 2013-06-28 |
| EP2601189A1 (en) | 2013-06-12 |
| ES2542764T3 (es) | 2015-08-11 |
| EA021359B1 (ru) | 2015-05-29 |
| WO2012017020A1 (en) | 2012-02-09 |
| CA2806015A1 (en) | 2012-02-09 |
| EP2601189B1 (en) | 2015-04-15 |
| CN103080104A (zh) | 2013-05-01 |
| UY33541A (es) | 2012-02-29 |
| TW201206900A (en) | 2012-02-16 |
| CN103080104B (zh) | 2015-04-08 |
| US20120035168A1 (en) | 2012-02-09 |
| KR20130096253A (ko) | 2013-08-29 |
| JP2013532713A (ja) | 2013-08-19 |
| AU2011287574B2 (en) | 2015-01-22 |
| AU2011287574A1 (en) | 2013-02-28 |
| MX2013001363A (es) | 2013-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082446A1 (es) | N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas | |
| AR079553A1 (es) | Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros. | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| AR077525A1 (es) | 4-aril-butan-1,3-diamidas y composiciones farmaceuticas | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR085354A1 (es) | Derivados de isoxazol para control de pestes invertebrados | |
| AR079224A1 (es) | Compuestos insecticidas basados en derivados de isoxazolina | |
| AR084430A1 (es) | Di/tri-aza-espiro-alcanos c | |
| AR081139A1 (es) | Uracilos herbicidas | |
| AR088616A1 (es) | Combinaciones de herbicida-protector selectivo que contienen amidas de acidos n-(tetrazol-5-il)-carbonico y n-(triazol-5-il)arilcarbonico | |
| AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
| CO6150164A2 (es) | Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR068386A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-3-benzazepinas, su procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos de los mismos en patologias asociadas a los canales hcn, tales como trastornos del aparato cardiovascular. | |
| AR086198A1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen | |
| BR112015032637A2 (pt) | derivados de pirrolopiridina ou pirazolopiridina | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR057915A1 (es) | Compuesto con estructura de cinamida de dos ciclos con actividad inhibitoria de la produccion de abeta40 y abeta42, un agente farmaceutico que lo comprende y el uso de este en el tratamiento de enfermedades mentales y neurodegenerativas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |